David Karow

Human Longevity announced that its board has appointed David Karow interim CEO. Karow previously served as HLI's chief of radiogenomics. Prior to HLI, Karow spent twenty years in research, clinical practice, and training at the University of California, San Diego, the University of California, Los Angeles, and the University of Michigan.